- Home
- HRTX vs COYA Comparison
HRTX vs COYA Comparison
Compare HRTX & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.05
HOLD
Current Price
$5.02
Company Overview
Basic Information| Metric | HRTX | COYA |
|---|---|---|
| Founded | 1983 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 126.6M |
| IPO Year | 2007 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HRTX | COYA |
|---|---|---|
| Price | $1.05 | $5.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.50 | ★ $15.80 |
| AVG Volume (30 Days) | ★ 1.8M | 149.3K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | $7,945,753.00 |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | $763.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.36 | ★ 123.57 |
| 52 Week Low | $0.74 | $3.71 |
| 52 Week High | $2.61 | $7.75 |
Technical Indicators
Market Signals| Indicator | HRTX | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 64.99 |
| Support Level | $1.03 | $4.50 |
| Resistance Level | $1.31 | $5.16 |
| Average True Range (ATR) | 0.05 | 0.27 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 98.41 | 95.47 |
Price Performance
Historical Comparison HRTX
COYA
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.